Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CryoPort, Inc. - Common Stock (NQ:CYRX)

9.040 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CryoPort, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Crude Oil Rises 1.5%; PepsiCo Earnings Top Views
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Thursday. The Dow traded up 0.15% to 34,397.80 while the NASDAQ rose 1.40% to 14,114.17. The S&P 500,... 
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Progressive Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Nasdaq Rises Over 100 Points; Delta Air Lines Posts Upbeat Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. The Dow traded up 0.13% to 34,392.36 while the NASDAQ rose 0.97% to 14,054.23. The S&P... 
Via Benzinga
Market Reacts To PPI Inflation Drop: 7 Stocks in the Spotlight Thursday
 
Via Benzinga
Why Shares of Cryoport are Tumbling Thursday
The cold supply chain company released preliminary second-quarter earnings. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2023
 
Via Benzinga
Why Are Cryoport Shares Plunging Today?
Cryoport Inc (NASDAQ: CYRX) shares are trading lower after the company released certain preliminary results for Q2 FY23 and updated its  
Via Benzinga
Looking Into CryoPort's Return On Invested Capital
 
Via Benzinga
CryoPort: Q1 Earnings Insights
 
Via Benzinga
Dow Gains Over 100 Points; US Producer Prices Rise 0.1% In June
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.31% to 34,454.88 while the NASDAQ rose 0.98%... 
Via Benzinga
Why Is Carvana (CVNA) Stock Down 5% Today?
Carvana (CVNA) stock is falling on Thursday after JPMorgan analyst Rajat Gupta downgraded the used-car retailer's shares. 
Via InvestorPlace
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
Galmed Pharmaceuticals (GLMD) stock is on the move Thursday after the medical company priced a public offering of its shares. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Is CryoPort (CYRX) Stock Down 26% Today?
CryoPort (CYRX) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for Q2 2023. 
Via InvestorPlace
Expert Ratings for CryoPort
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
Cryoport: Temperature-Controlled Supply Chain Solutions Provider Sees Almost 30% Bump In Revenues
Robert Stefanovich, CFO of Cryoport, Inc. (NASDAQ: CYRX), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
Stocks Extend Slump, Head For Weekly Losses
Stocks are extending their premarket losses, with the Dow Jones Industrial Average down 409 points. 
Via Talk Markets
Kratos Defense & Security, Zeta Global, Beacon Roofing Supply And Other Big Stocks Moving Higher On Friday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday
Oppenheimer boosted the price target for Universal Display Corporation (NASDAQ: OLED) from $150 to $160. Oppenheimer analyst Martin Yang maintained an Outperform rating on the stock. Universal Display... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.